Chimovits Erez's Form 4 filing
Braveheart Bio, Inc. (BRVE) · filed Aug 11, 2026
- Accession no.
- 0000947871-26-000783
- Filed
- Aug 11, 2026, 5:31 PM ET
- Trade date
- Aug 7, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market purchases total $34.9M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chimovits ErezCIK 0001706399 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Common Stock | CConversionAcquired | +9,132,420 | –F1 | – | 10,235,159 | Indirect | Duplicate filing |
| Aug 7, 2026 | Common Stock | PPurchaseAcquired | +1,666,667 | $18.00 | +$30,000,006 | 11,901,826 | Indirect | Duplicate filing |
| Aug 7, 2026 | Common Stock | PPurchaseAcquired | +273,333 | $18.00 | +$4,919,994 | 273,333 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Common Stock | CConversionDisposed | −9,132,420 | $0.00 | $0 | 0 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-4.38 basis upon the closing of the Issuer's initial public offering on August 7, 2026 without payment of consideration. The Series A Preferred Stock has no expiration date.
Referenced by the price of 1 transaction in Table I.